Darkoh C, Brown EL, Kaplan HB, et al. Bile salt inhibition of host cell damage by clostridium difficile toxins. PLoS One[R]. 2013 Nov 11,8(11):e79631.
[2]
Barbut F, Mastrantonio P, Delmée M, et al. Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates[J]. Clin Microbiol Infect, 2007 Nov,13(11):1048-1057.
[3]
Denève C, Bouttier S, Dupuy B, et al. Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains[J]. Antimicrob Agents Chemother, 2009 Dec, 53(12):5155-5162.
[4]
Antunes A, Camiade E, Monot M, et al. Global transcriptional control by glucose and carbon regulator CcpA in Clostridium difficile[J]. Nucleic Acids Res, 2012 Nov, 40(21):10701-10718.
[5]
Onderdonk AB, Lowe BR, Bartlett JG. Effect of environmental stress on Clostridium difficile toxin levels during continuous cultivation [J]. Appl Environ Microbiol,1979 Oct,38(4):637-641.
[6]
Gerber M, Walch C, L?ffler B, et al. Ackermann G. Effect of sub-MIC concentrations of metronidazole, vancomycin, clindamycin and linezolid on toxin gene transcription and production in Clostridium difficile[J]. J Med Microbiol， 2008 Jun, 57(Pt 6):776-783.
[7]
Drummond LJ, Smith DG, Poxton IR. Effects of sub-MIC concentrations of antibiotics on growth of and toxin production by Clostridium difficile [J]. J Med Microbiol, 2003 Dec,52(Pt 12):1033-1038.
[8]
WhitingJL, ChengN, ChowAW.Interactions of ciprofloxacin with clindamycin,metronidazole, cefoxitin, cefotaximeand mezlocillinagainst grampositive and gram-negative anaerobic bacteria [J]. Antimicrob Agents Chemother, 1987 Sep,31(9): 1379-1382.
[9]
Clutter DS, Dubrovskaya Y, Merl MY, et al. Fidaxomicin versus conventional antimicrobial therapy in 59 recipients of solid organ and hematopoietic stem cell transplantation with clostridium difficile-associated diarrhea,[J].Antimicrob Agents Chemother 2003 Sep,57(9):4501-4505
[10]
Babakhani F, Bouillaut L, Gomez A, et al. Fidaxomicin inhibits spore production in Clostridium difficile. Clin Infect Dis [J]. 2012 Aug,55 Suppl 2:S162-169.
[11]
Davies J, Spiegelman GB, Yim G. The world of subinhibitory antibiotic concentrations [J]. Curr Opin Microbiol, 2006 Oct,9(5):445-453.
[12]
Baines SD, Freeman J, Wilcox MH. Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut monde [J].J Anitimicrob Chemother,2005 Jun,55(6):974-982.
